2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 743

Behavior of Complement Levels and Risk of Organ Involvement in SLE Patients
Abstract Number: 744

Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous
Abstract Number: 745

Changes in Serum Albumin Levels Correlate Highly with Severity and Activity of SLE
Abstract Number: 746

Multi-Center Delphi Exercise Reveals Important Key Items in Classifying SLE
Abstract Number: 747

Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study
Abstract Number: 748

Comparison of Systemic Lupus Erythematosus in 3 Different Asian Ethnic Groups: Results from the 1000 Faces of Lupus Cohort
Abstract Number: 749

Microvesicles Containing Nucleic Acids and Expressing Immunoglobulins and HMGB1 Are Abundant in Patients with Systemic Lupus Erythematosus
Abstract Number: 750

Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis
Abstract Number: 751

Rituximab Induced Serum Sickness: A Systematic Review
Abstract Number: 752

A Strong Association Between Gout and Diuretic Use Among Lupus Patients
Abstract Number: 753

Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy
Abstract Number: 754

Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide
Abstract Number: 755

Validating the RAIL Algorithm in Adult Lupus Nephritis Patients
Abstract Number: 756

Axl, Ferritin, IGFBP2 and TNFR2 As Biomarkers in Systemic Lupus Erythematosus
Abstract Number: 757

The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].